Skip to main content
Signal8
Launch Terminal

aTYR PHARMA INC (ATYR)

aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

aTyr Pharma, Inc. logo

aTyr Pharma, Inc.

NASDAQ:ATYRHealthcare
-8.01%$4.94
AH$4.94+0.00%vs close
Mkt Cap-
Float2.44M
O/S-
Vol
$ Vol
RVOL
Inst Own39.5%
Earnings
Dilution
aTyr Pharma, Inc. logoNASDAQ:ATYR$4.94-8.01%
Upcoming Catalysts
Phase Distribution
9 lead-sponsored trials·1 active·8 completed
Phase 1/26
Phase 22
Phase 31
(1 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis

    Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg

    Pulmonary Sarcoidosis

    Enrollment
    268
    Start
    Sep 2022
    Primary Completion
    Jun 2025
    Completion
    Jul 2025
    NCT05415137
  • Phase 2
    Completed

    Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

    Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg

    SARS-CoV-2 (COVID-19) Severe Pneumonia

    Enrollment
    36
    Start
    Jun 2020
    Primary Completion
    Oct 2020
    Completion
    Oct 2020
    NCT04412668
  • Phase 2
    Recruiting

    Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

    efzofitimod 450 mg, efzofitimod 270 mg

    Interstitial Lung Disease

    Enrollment
    25
    Start
    Oct 2023
    Primary Completion
    Apr 2026est.
    Completion
    Apr 2026est.
    NCT05892614
  • Phase 1/2
    Completed

    Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy

    Placebo, ATYR1940

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    Enrollment
    20
    Start
    Sep 2014
    Primary Completion
    Dec 2015
    Completion
    Dec 2015
    NCT02239224
  • Phase 1/2
    Completed

    Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study Extension

    ATYR1940

    Facioscapulohumeral Muscular Dystrophy

    Enrollment
    9
    Start
    Aug 2015
    Primary Completion
    May 2016
    Completion
    May 2016
    NCT02531217
  • Phase 1/2
    Completed

    Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)

    ATYR1940, Placebo

    Limb-Girdle Muscular Dystrophies, Facioscapulohumeral Muscular Dystrophy

    Enrollment
    18
    Start
    Nov 2015
    Primary Completion
    Oct 2016
    Completion
    Oct 2016
    NCT02579239
  • Phase 1/2
    Completed

    Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy

    ATYR1940

    Facioscapulohumeral Muscular Dystrophy (FSHD)

    Enrollment
    8
    Start
    Mar 2016
    Primary Completion
    Dec 2016
    Completion
    Dec 2016
    NCT02603562
  • Phase 1/2
    Completed

    Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)

    ATYR1940

    Facioscapulohumeral Muscular Dystrophy, Limb Girdle Muscular Dystrophy

    Enrollment
    8
    Start
    Jul 2016
    Primary Completion
    Apr 2017
    Completion
    Apr 2017
    NCT02836418
  • Phase 1/2
    Completed

    Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis

    Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo

    Pulmonary Sarcoidosis

    Enrollment
    37
    Start
    Jan 2019
    Primary Completion
    Jun 2021
    Completion
    Jun 2021
    NCT03824392
Search ClinicalTrials.gov for “aTYR PHARMA”